الفهرس | Only 14 pages are availabe for public view |
Abstract This study aimed at exploring the hypothesis that the Ologen implant and the bevacizumab may be safe and effective alternatives to the use of MMC for trabeculectomy procedures. from our results; we confirm the effectiveness of MMC in controlling scar formation after trabeculectomy, but it was associated with some side effects. We conclude that the Ologen implant may be a safe and effective alternative to MMC in terms of IOP reduction, and it may avoid the side effects associated with the use of MMC. With 1.25mg subconjunctival bevacizumab in trabeculectomy, we cannot reach a conclusion that it can be a MMC substitute in augmented trabeculectomy, as it had a lower success rate and was associated with some complications. Recommendations A larger randomized trials and a longer follow-up period are warranted to determine the possible long-term complications of subconjunctival bevacizumab and Ologen and their effects on the outcome of trabeculectomy. The dose and frequency of subconjunctival injection of anti-VEGF may need more investigational studies to reach its optimal effect as an anti-scarring agent after trabeculectomy. |